Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network
| Autor: | E. Raefsky, James E. Bradof, John D. Zubkus, W. H. Liggett, Marshall T. Schreeder, David R. Spigel, John D. Hainsworth, D. A. Yardley, F. A. Greco, D. Petrone, D. V. Woytowitz |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Proteinuria Bevacizumab business.industry medicine.medical_treatment Phases of clinical research Carboplatin Surgery Radiation therapy Irinotecan chemistry.chemical_compound chemistry Internal medicine Toxicity medicine medicine.symptom business Chemoradiotherapy medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:7050-7050 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 7050 Background: Preclinical studies have demonstrated VEGF expression in SCLC, a target that may predict response to treatment with anti-angiogenic agents such as B. Few trials have incorporated these agents into the treatment of SCLC, providing rationale for studying B in addition to chemoradiotherapy. Methods: The primary endpoints of this multicenter phase II study were to assess the safety and response rate (RR) of I/C/RT followed by B in patients (pts) with limited-stage SCLC. Treatment consisted of: C AUC=5 IV D1, I 50mg/m2 IV D1, 8 Q 21D for 4 cycles, and concurrent RT 1.8 Gy QD to a total of 61.2 Gy, beginning with the 3rd cycle. 3rd and 4th cycles were 28D each. Pts were restaged after 4 cycles. Pts without progression or undue toxicity received B 10 mg/kg IV Q 14D for 10 doses. Eligibility criteria included: measurable disease, ECOG PS 0–1, adequate organ function |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|